派安普利单抗抗肿瘤治疗的研究进展  

Research Progress of Penpulimabin Antitumor Therapy

作　　者：袁嘉怡 李国元[2] 

机构地区：[1]青海大学研究生院,青海 西宁 [2]青海大学附属医院肿瘤内科,青海 西宁

出　　处：《临床个性化医学》2024年第2期425-429,共5页Journal of Clinical Personalized Medicine

摘　　要：近年来,随着恶性肿瘤发病率的不断增高,恶性肿瘤已成为全球面临的重大健康问题之一。派安普利单抗是目前世界上唯一进行Fc段改造并采用IgG1亚型的新型差异化PD-1单抗,能够有效增强免疫治疗疗效,减少不良反应,部分临床实验已经证实派安普利单抗单药或联合其他疗法治疗恶性肿瘤表现出良好的疗效及安全性。本文就派安普利单抗抗肿瘤治疗的研究进展作一简要综述。In recent years, with the increasing incidence of malignant tumors, malignant tumors have become one of the major health problems facing the world. Penpulimab is the only new differentiated PD-1 monoclonal antibody with Fc segment modification and IgG1 subtype in the world, which can effectively enhance the efficacy of immunotherapy and reduce the adverse effects, and some clinical trials have confirmed that Penpulimab alone or in combination with other therapies for the treatment of malignant tumors has shown good efficacy and safety. In this article, we would like to briefly review the research progress on the antitumor therapy of Penpulimab.

关 键 词：派安普利单抗 抗肿瘤治疗 PD-1/PD-L1抑制剂 免疫治疗 

分 类 号：R73[医药卫生—肿瘤]